Latest News and Press Releases

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- Cointelegraph Research has released a new analysis examining how the United Nations Development Programme (UNDP) is testing blockchain technology to...

Nonpartisan research firm provides data for ABC News, CNN, The Associated Press, and other major networks

PALO ALTO, CA, March 25, 2026 (GLOBE NEWSWIRE) -- Today, the Latino Business Action Network (LBAN), in collaboration with the Stanford Graduate School of Business (GSB), released the 11th Annual...

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist

Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025Group net sales increased 7.3%* to EUR 27.8 billion in...

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.

BlueMatrix names David Nable CEO, Patricia Horotan CSO to drive AI strategy and scale its platform as core infrastructure for AI-driven research workflows.

AFB Research Reveals Attitudes Toward and Reach of AI with Focus on Disability

Real-world data advances new insights into donor selection, benchmarks for patient infection prevention and comparative outcomes in a modern post-transplant cyclophosphamide (PTCy) era MINNEAPOLIS,...